An Open-Label, Single Center, Nonrandomized, Phase 1 Study to Evaluate Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 17 Dec 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2019.
- 17 Dec 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2019.
- 17 Dec 2018 Status changed from recruiting to active, no longer recruiting.